Bioxytran's ProLectin-M achieves 90% Day-5 viral clearance in Phase 1b/2a COVID-19 study

BIOXYTRAN, INC

Phase 1b/2a trial: 39 patients; highest dose 16,800 mg/day showed 90% Day-5 viral clearance vs 20% placebo (p=0.001).
90% of highest-dose cohort had ≥2-point improvement on WHO Ordinal Scale by Day 5 vs 20% placebo.
No serious adverse events, no treatment-related discontinuations; favorable safety profile across all doses.
ProLectin-M targets galectins to block viral entry; potential broad-range antiviral beyond COVID-19.
Company plans larger studies to evaluate ProLectin-M as first-line oral antiviral therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.